BEIGENE：2024ResponsibleBusinessandSustainabilityReport.pdf

1、Responsible Business&Sustainability Report2024Table of ContentsA Letter from Leadership.3Our Mission,Vision&Values.5Our Approach to Responsible Business&Sustainability.6Guiding Principles.7Our Responsible Business&Sustainability Strategy.82024 Goals&Progress.11Advancing Global Health.12Our Approach

2、to Innovation&Clinical Development.13Pursuing Broad Access for Our Medicines.19BeiGene Foundation.22Supporting Patients.23Empowering Our Colleagues.26Building Our Team.27Colleague Engagement&Support.28Compensation&Benefits.29Career Development.30A Culture of Belonging.33Colleague Volunteerism.34Heal

3、th&Safety.35Innovating Sustainably.372024 Environmental Goals&Progress.38Our Environmental Governance.39Our Environmental Strategy.40Assessing Our Impacts&Risks.40Taking Action and Goal-Setting.43Our Environmental Metrics.45Operating Responsibly.49Corporate Governance.50Enterprise Risk Management.53

4、Our Policies.53Privacy,and Data Ethics.55Product Quality Control Systems.57Commitment to Transparency.59Responsible Procurement.60Appendix.61GRI&HKEX Index.62STAR Index.78SASB Index.92Task Force on Climate-Related Financial Disclosures.95Data Tables.96About This Report.100Forward-Looking Statement.1

5、002024 BeiGene Responsible Business&Sustainability Report2INTRODUCTIONOUR APPROACH TO RESPONSIBLEBUSINESS&SUSTAINABILITYADVANCING GLOBAL HEALTHEMPOWERINGOUR COLLEAGUESINNOVATINGSUSTAINABLYOPERATINGRESPONSIBLYAPPENDIXA Letter from LeadershipOn behalf of the entire BeiGene organization,we are pleased

6、to share our 2024 Responsible Business&Sustainability(RB&S)Report.This was a milestone year for us in many respects.Our total revenues for the year grew to$3.8 billion,an increase of$1.4 billion from 2023,we advanced 13 new molecular entities(NME)into the clinic,and approximately 95%of our clinical